Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBUPHINE vs FLEXERIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Treatment of opioid dependence,Off-label: management of chronic pain,Off-label: treatment of opioid-induced constipation
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Terminal elimination half-life: 37 hours (range 24-48 h) due to slow release from tissue binding and enterohepatic recirculation; contributes to prolonged dosing interval (every 4 weeks) and delayed withdrawal onset.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Primarily metabolized by CYP3A4 and CYP2B6 to norbuprenorphine (active). Glucuronidation via UGT1A1 and UGT2B7.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Primarily renal (70-80% as unchanged drug and active metabolite norbuprenorphine), biliary/fecal (20-30%)
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
96% bound to plasma proteins (primarily alpha- and beta-globulins, minor albumin binding)
~93% bound to plasma proteins, primarily albumin.
Vd: 2.5-3.0 L/kg; large distribution due to high lipophilicity and extensive tissue binding, indicating slow redistribution.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Sublingual: 30-50% (due to first-pass metabolism). Transdermal: 15-20% (rate-controlled delivery). Oral: <10% (extensive first-pass) and not clinically used.
Oral: ~33% due to extensive first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. For severe (Cr Cl <30 m L/min): not recommended.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Weight-based: 0.1-0.2 mg/kg sublingually once daily, titrate up to maximum 0.4 mg/kg/day; maximum 24 mg/day.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Start at lower end of dosing range (e.g., 4-8 mg sublingually once daily) with cautious titration due to increased sensitivity and risk of CNS depression.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
Risk of respiratory depression, especially with concurrent use of CNS depressants or in patients with compromised respiratory function. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Potential for life-threatening QT prolongation at high doses.
None
Severe respiratory depression; misuse and abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; hepatotoxicity; QT prolongation; dental decay with sublingual use; opioid withdrawal syndrome with naloxone coadministration.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Hypersensitivity to buprenorphine; severe respiratory depression; acute or severe bronchial asthma; paralytic ileus; use of monoamine oxidase inhibitors within 14 days.
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
No specific food interactions are reported for buprenorphine. However, grapefruit and grapefruit juice may theoretically affect metabolism via CYP3A4 inhibition, altering drug levels. Avoid excessive intake.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are no adequate human studies. First trimester exposure may be associated with neural tube defects; second and third trimester exposure may cause fetal hydantoin syndrome (craniofacial anomalies, growth retardation, neurodevelopmental delay) and increased risk of hemorrhage due to vitamin K depletion.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
Probupine is excreted into breast milk. M/P ratio is approximately 0.45. Infant daily dose is estimated at 1-5% of maternal weight-adjusted dose. Reports of sedation and poor suckling in breastfed infants; cautious use recommended, especially in neonates with UDP-glucuronosyltransferase deficiency.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Increased hepatic clearance during pregnancy, especially third trimester, necessitating dose increases up to 30-50% to maintain therapeutic levels. Postpartum dose should be reduced to prepregnancy levels within 2 weeks. Monitor trough levels every 2 weeks during pregnancy and adjust accordingly.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Probupine is not a recognized drug; verify spelling. If referring to buprenorphine, note that it is a partial mu-opioid agonist used for opioid use disorder and pain. Monitor for respiratory depression, especially when combined with CNS depressants. Due to its partial agonist activity, it has a ceiling effect for respiratory depression. High doses may precipitate withdrawal in opioid-dependent patients. Naloxone may not fully reverse buprenorphine effects; consider higher doses or respiratory support.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol, benzodiazepines, and other sedatives unless directed by your physician, as they increase risk of serious side effects.,Do not stop suddenly; withdrawal may occur. Follow a tapering schedule if discontinuing.,Keep out of reach of children and others; misuse can cause addiction, overdose, or death.,Store safely at room temperature, away from moisture and heat.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBUPHINE vs FLEXERIL, answered by our medical review team.
PROBUPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.. FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBUPHINE and FLEXERIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBUPHINE is: Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.. The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBUPHINE and FLEXERIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBUPHINE is classified as Category C. Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.